<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32207340</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-3892</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2020</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Cell transplantation</Title><ISOAbbreviation>Cell Transplant</ISOAbbreviation></Journal><ArticleTitle>Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>963689720913494</StartPage><MedlinePgn>963689720913494</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">0963689720913494</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/0963689720913494</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal disease of motor neuron degeneration in the brain and spinal cord. Progressive paralysis of the diaphragm and other respiratory muscles leading to respiratory dysfunction and failure is the most common cause of death in ALS patients. Respiratory impairment has also been shown in animal models of ALS. Vascular pathology is another recently recognized hallmark of ALS pathogenesis. Central nervous system (CNS) capillary damage is a shared disease element in ALS rodent models and ALS patients. Microvascular impairment outside of the CNS, such as in the lungs, may occur in ALS, triggering lung damage and affecting breathing function. Stem cell therapy is a promising treatment for ALS. However, this therapeutic strategy has primarily targeted rescue of degenerated motor neurons. We showed functional benefits from intravenous delivery of human bone marrow (hBM) stem cells on restoration of capillary integrity in the CNS of an superoxide dismutase 1 (SOD1) mouse model of ALS. Due to the widespread distribution of transplanted cells via this route, administered cells may enter the lungs and effectively restore microvasculature in this respiratory organ. Here, we provided preliminary evidence of the potential role of microvasculature dysfunction in prompting lung damage and treatment approaches for repair of respiratory function in ALS. Our initial studies showed proof-of-principle that microvascular damage in ALS mice results in lung petechiae at the late stage of disease and that systemic transplantation of mainly hBM-derived endothelial progenitor cells shows potential to promote lung restoration via re-established vascular integrity. Our new understanding of previously underexplored lung competence in this disease may facilitate therapy targeting restoration of respiratory function in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garbuzova-Davis</LastName><ForeName>Svitlana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5816-0937</Identifier><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shell</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Hilmi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hailu</LastName><ForeName>Surafuale</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willing</LastName><ForeName>Alison E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanberg</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borlongan</LastName><ForeName>Cesario V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Transplant</MedlineTA><NlmUniqueID>9208854</NlmUniqueID><ISSNLinking>0963-6897</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055806" MajorTopicYN="N">Microvessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="Y">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">lungs</Keyword><Keyword MajorTopicYN="N">microvasculature</Keyword><Keyword MajorTopicYN="N">repair</Keyword><Keyword MajorTopicYN="N">respiratory dysfunction</Keyword></KeywordList><CoiStatement><b>Declaration of Conflicting Interests:</b> The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32207340</ArticleId><ArticleId IdType="pmc">PMC7444221</ArticleId><ArticleId IdType="doi">10.1177/0963689720913494</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9(5):303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun AT, Caballero-Eraso C, Lechtzin N. Amyotrophic lateral sclerosis and the respiratory system. Clin Chest Med. 2018;39(2):391&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">29779597</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NL, Van Dyke J, Nashold L, Satriotomo I, Suzuki M, Mitchell GS. Ventilatory control in ALS. Respir Physiol Neurobiol. 2013;189(2):429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361018</ArticleId><ArticleId IdType="pubmed">23692930</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155(2):401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124(Pt 10):2000&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J, Hansen-Flaschen J, Wileyto EP, Schwab RJ, Elman L, Kawut SM. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respir J. 2019;53(4):1802237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684229</ArticleId><ArticleId IdType="pubmed">30728207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya R, Harvey RA, Abraham K, Rosen J, Mehta P. Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">30892090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon J. Riluzole and ALS therapy. Wien Med Wochenschr. 1996;146(9&#x2013;10):185&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873431</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):191&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">13129806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171(4):725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue-Shibui A, Kato M, Suzuki N, Kobayashi J, Takai Y, Izumi R, Kawauchi Y, Kuroda H, Warita H, Aoki M. Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study. BMC Neurol. 2019;19(1):72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487018</ArticleId><ArticleId IdType="pubmed">31029113</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Matias T, Coelho F, Evangelista T, Pinto A, Lu&#xed;s ML. Motor neuron disease presenting with respiratory failure. J Neurol Sci. 1996;139(Suppl):117&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N. Respiratory effects of amyotrophic lateral sclerosis: problems and solutions. Respir Care. 2006;51(8):871&#x2013;881; discussion 881-884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16867198</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Pradat P-F, Salachas F, Bruneteau G, Forestier NL, Seilhean D, Hauw J-J, Meininger V. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9(1):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17924236</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPALS Writing Committee, DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14(9):883&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">26234554</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Gromicho M, Swash M, deCarvalho M. Cervical muscle weakness is a marker of respiratory dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;91(3):323&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">31694878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology. 2001;57(11):2040&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. Amyotroph Lateral Scler. 2010;11(4):379&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Vescovi A, Cantello R, Gelati M, Vercelli A. Stem cells therapy for ALS. Expert Opin Biol Ther. 2016;16(2):187&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">26558293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms. Rev Neurosci. 2017;28(7):725&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">28599400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanberg PR, Eve DJ, Willing AE, Garbuzova-Davis S, Tan J, Sanberg CD, Allickson JG, Cruz LE, Borlongan CV. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20(1):85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">20887684</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Savelieff MG, Sakowski SA, Feldman EL. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs. 2019;28(6):525&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrari D, Andjus PR, Buzanska L, Cantello R, De Marchi F, Gelati M, Giniatullin R, Glover JC, Grilli M, Kozlova EN, et al. Advances in stem cell therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2018;18(8):865&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">30025485</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi G, Corti S. Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56(10):6703&#x2013;6715.</Citation><ArticleIdList><ArticleId IdType="pubmed">30911936</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Calzarossa C, Cova L, Ticozzi N. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement? CNS Neurol Disord Drug Targets. 2010;9(3):314&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20406179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014;32(5):1099&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4225704</ArticleId><ArticleId IdType="pubmed">24448926</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Svendsen S, Svendsen CN. The past, present and future of stem cell clinical trials for ALS. Exp Neurol. 2014;262(Pt B):127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">24613827</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykov&#xe1; E, Rychmach P, Drahor&#xe1;dov&#xe1; I, Konr&#xe1;dov&#xe1; &#x160;, R&#x16f;&#x17e;i&#x10d;kov&#xe1; K, Vo&#x159;&#xed;&#x161;ek I, Forostyak S, Homola A, Bojar M. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial. Cell Transplant. 2017;26(4):647&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5661219</ArticleId><ArticleId IdType="pubmed">27938483</ArticleId></ArticleIdList></Reference><Reference><Citation>Moviglia GA, Moviglia-Brandolino MT, Varela GS, Albanese G, Piccone S, Echegaray G, Martinez G, Blasseti N, Farias J, Farina P, Perusso A, et al. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012;21(Suppl 1):S57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez HR, Molina-Lopez JF, Gonz&#xe1;lez-Garza MT, Moreno-Cuevas JE, Caro-Osorio E, Gil-Valadez A, Gutierrez-Jimenez E, Zazueta-Fierro OE, Meza JA, Couret-Alcaraz P, Hernandez-Torre M. Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility. Cell Transplant. 2012;21(9):1899&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">23356668</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NL, Gowing G, Satriotomo I, Nashold LJ, Dale EA, Suzuki M, Avalos P, Mulcrone PL, McHugh J, Svendsen CN, Mitchell GS. Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2013;187(5):535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733409</ArticleId><ArticleId IdType="pubmed">23220913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, Maragakis NJ. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci. 2008;11(11):1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656686</ArticleId><ArticleId IdType="pubmed">18931666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-L&#xf3;pez FJ, Guardiola J, Izura V, G&#xf3;mez-Espuch J, Iniesta F, Blanquer M, L&#xf3;pez-San Rom&#xe1;n J, Saez V, De Mingo P, Mart&#xed;nez S, Moraleda JM. Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone marrow mononuclear cells in patients with amyotrophic lateral sclerosis. Respir Physiol Neurobiol. 2016;221:54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">26593639</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Rodrigues MCO, Hernandez-Ontiveros DG, Louis MK, Willing AE, Borlongan CV, Sanberg PR. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 2011;1398:113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues MCO, Hernandez-Ontiveros DG, Louis MK, Willing AE, Borlongan CV, Sanberg PR, Voltarelli JC, Garbuzova-Davis S. Neurovascular aspects of amyotrophic lateral sclerosis. Int Rev Neurobiol. 2012;102:91&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22748827</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, Sanberg PR. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2(11): e1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MCO, Haller E, Frisina-Deyo A, Mirtyl S, Sallot S, Saporta S, Borlongan CV, Sanberg PR. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, Pochet R. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">19748495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O&#x2019;Banion MK, Stojanovic K, Sagare A, Boillee S, Cleveland DW, Zlokovic BV. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, Morimoto N, Kurata T, Takehisa Y, Ikeda Y, Matsuura T, Abe K. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Bowser R, Appel SH. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72(18):1614&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35(6):518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwangbo C, Lee H-W, Kang H, Ju H, Wiley DS, Papangeli I, Han J, Kim J-D, Dunworth WP, Hu X, Lee S, et al. Modulation of endothelial bone morphogenetic protein receptor type 2 activity by vascular endothelial growth factor receptor 3 in pulmonary arterial hypertension. Circulation. 2017;135(23):2288&#x2013;2298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5523010</ArticleId><ArticleId IdType="pubmed">28356442</ArticleId></ArticleIdList></Reference><Reference><Citation>Madurga A, Golec A, Pozarska A, Ishii I, Mi&#x17e;&#xed;kov&#xe1; I, Nardiello C, Vad&#xe1;sz I, Herold S, Mayer K, Reichenberger F, Fehrenbach H, et al. The H2S-generating enzymes cystathionine &#x3b2;-synthase and cystathionine &#x3b3;-lyase play a role in vascular development during normal lung alveolarization. Am J Physiol Lung Cell Mol Physiol. 2015;309(7):L710&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">26232299</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Thomson A, Falco D, Ahmad S, Staffetti J, Steiner G, Abraham S, James G, Mahendrasah A, Sanberg PR, et al. Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep. 2017;7(1):884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429840</ArticleId><ArticleId IdType="pubmed">28408761</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Navarro S, Besong TE, Boccio KJ, Hailu S, Khatib M, Sanberg PR, Appel SH, Borlongan CV. Transplantation of human bone marrow stem cells into symptomatic ALS mice enhances structural and functional blood-spinal cord barrier repair. Exp Neurol. 2018;310:33&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203661</ArticleId><ArticleId IdType="pubmed">30172620</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Haller E, Eve DJ, Navarro S, Steiner G, Mahendrasah A, Hailu S, Khatib M, Boccio KJ, Borlongan CV, et al. Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci Rep. 2019;9(1):5280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437219</ArticleId><ArticleId IdType="pubmed">30918315</ArticleId></ArticleIdList></Reference><Reference><Citation>Eve DJ, Steiner G, Mahendrasah A, Sanberg PR, Kurien C, Thomson A, Borlongan CV, Garbuzova-Davis S. Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier. Oncotarget. 2018;9(12):10621&#x2013;10634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828209</ArticleId><ArticleId IdType="pubmed">29535831</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190292</ArticleId><ArticleId IdType="pubmed">19099374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankersley CG, Haenggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol. 2007;102(3):926&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NL, Satriotomo I, Harrigan DJ, Mitchell GS. Acute intermittent hypoxia induced phrenic long-term facilitation despite increased SOD1 expression in a rat model of ALS. Exp Neurol. 2015;273:138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644466</ArticleId><ArticleId IdType="pubmed">26287750</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KL, Dhaibar HA, Dayton RD, Cananzi SG, Mayhan WG, Glasscock E, Klein RL. Severe respiratory changes at end stage in a FUS-induced disease state in adult rats. BMC Neurosci. 2016;17(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5086065</ArticleId><ArticleId IdType="pubmed">27793099</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; PD, Mitzner W. Airway-parenchymal interdependence. Compr Physiol. 2012;2(3):1921&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557883</ArticleId><ArticleId IdType="pubmed">23723029</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvin CG, Bates JHT. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003;4:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC184039</ArticleId><ArticleId IdType="pubmed">12783622</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Mustafa H, Llauget A, Boccio KJ, Sanberg PR, Appel SH, Borlongan CV. Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS. Brain Res. 2019;1724:146428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779528</ArticleId><ArticleId IdType="pubmed">31493389</ArticleId></ArticleIdList></Reference><Reference><Citation>Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">20703216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine. 2013;44(1):11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726927</ArticleId><ArticleId IdType="pubmed">23203002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, Deregibus MC, Galimi F, Romagnoli R, Salizzoni M, Tetta C, Segoloni GP, et al. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant. 2012;21(6):1305&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">22455973</ArticleId></ArticleIdList></Reference><Reference><Citation>Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007;110(7):2440&#x2013;2448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536014</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O&#x2019;Kane CM, Krasnodembskaya AD. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med. 2017;196(10):1275&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694830</ArticleId><ArticleId IdType="pubmed">28598224</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone ML, Zhao Y, Robert Smith J, Weiss ML, Kron IL, Laubach VE, Sharma AK. Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. Respir Res. 2017;18(1):212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740880</ArticleId><ArticleId IdType="pubmed">29268735</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba F. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia. Pediatr Int. 2019;61(10):945&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">31487104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>